Sanctura XR to begin Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Indevus is on track to initiate a Phase III program for its once-daily Sanctura (trospium) formulation Sanctura XR this summer, "with a goal of submitting an NDA in the second half of next year," the firm announces June 15. Esprit Pharma is Indevus' new co-promotion partner for the Sanctura overactive bladder therapy brand under a July 1 deal; Pliva had been Indevus' previous marketing partner...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.